Moxifloxacino Kabi (Moxifloxacin Hydrochloride)

Moxifloxacin, the active ingredient in Moxifloxacino Kabi, is a fluoroquinolone antibiotic presented as an injectable solution for intravenous use. It is indicated for the treatment of serious bacterial infections such as community‑acquired pneumonia, acute bacterial sinusitis, and complicated skin or intra‑abdominal infections in adult patients.

GNH USA supplies Moxifloxacino Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The product complies with EU regulatory standards.

Moxifloxacin is a fluoroquinolone antibiotic used to treat infections caused by susceptible bacteria.

- Community‑acquired bacterial pneumonia: achieves bacterial eradication and clinical cure. - Acute bacterial sinusitis: reduces symptoms and clears infection. - Acute exacerbations of chronic bronchitis: improves pulmonary function and resolves infection. - Complicated skin and skin structure infections: provides bacterial clearance and promotes wound healing. - Complicated intra‑abdominal infections: achieves source control and infection resolution.

Moxifloxacin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea - Diarrhea - Headache - Dizziness - Rash - Elevated liver enzymes

Serious or Rare Side Effects: - Tendon rupture - QT interval prolongation - Severe allergic reactions (anaphylaxis) - Clostridioides difficile‑associated diarrhea - Peripheral neuropathy - Hepatotoxicity

Use of Moxifloxacino Kabi requires careful clinical assessment and monitoring.

- Renal impairment: adjust dose if necessary and monitor renal function. - Hepatic dysfunction: monitor liver enzymes and consider dose modification. - QT prolongation risk: avoid in patients with known arrhythmias or concurrent QT‑prolonging drugs. - Tendon disorders: advise patients to report tendon pain or swelling promptly. - Pregnancy Category C: use only when the potential benefit justifies the potential risk to the fetus. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Moxifloxacino Kabi can interact with several medicines, affecting safety or efficacy.

Major Interactions (Avoid): - Antacids containing aluminum or magnesium: reduce absorption of moxifloxacin. - Warfarin: increased risk of bleeding. - Theophylline: increased toxicity risk. - Cyclosporine: elevated cyclosporine concentrations. - QT‑prolonging agents: additive risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - NSAIDs: heightened risk of central nervous system effects. - Corticosteroids: increased incidence of tendon rupture. - Diuretics: potential electrolyte disturbances. - Rifampin: may reduce moxifloxacin efficacy. - HIV protease inhibitors: possible alteration of drug metabolism.